Sun Pharma most exposed Indian company to Trump's new tariff threat, warns Jefferies

US trade policies, especially tariffs, can significantly impact Indian pharmaceutical exporters. Companies with a high reliance on specific product categories or manufacturing locations outside India are particularly vulnerable.

Consider a short position on Sun Pharma or reduce long exposure, especially if tariff news is confirmed.

For Indian markets, this story mainly matters for SUNPHARMA and the pharma pocket. The current signal is bearish, so traders should look for follow-through in price, volume, and sector breadth instead of reacting to the headline alone.

Watch whether the next market session confirms the setup described here: Most exposed Indian company to potential US tariffs on medicines, especially specialty and innovative products. Also track volume confirmation, sector participation, and whether the move holds beyond the first reaction.

• •Sun Pharma faces significant exposure to potential US tariffs on medicines.
• •Jefferies warns that specialty and innovative products manufactured in South Korea and the EU could face levies up to 15%.
• •The US administration is reportedly preparing these tariffs, with an announcement possibly today.
• •Risk flag: Tariffs being implemented as threatened
• •Risk flag: Broader trade war escalation impacting other pharma exports